SPRO Spero Therapeutics, Inc.
Company Analysis
Latest News
Spero Therapeutics COO Timothy Keutzer to Retire Effective December 31, 2026
Spero Therapeutics announced that Chief Operating Officer (COO) Timothy Keutzer will retire from the company at the end of the year. Following his retirement,...
🟢 Spero Therapeutics is trading 6.5% up in pre-market; no clear company-specific catalyst identified
Spero Therapeutics is trading at $1.14, up 6.52%, with no clear company-specific catalyst identified for the pre-market gain. - The price compares with the...
🟢 Spero Therapeutics is trading 5% up today amid biotech-sector strength
Spero Therapeutics is trading at $1.18, up 5.36%; biotech-sector strength is supportive. - XBI was up 2.10% during regular trading. - No clear...
🟢 Spero Therapeutics is trading 5% up in pre-market; no clear catalyst identified
Spero Therapeutics is trading 5.36% up in pre-market at $1.18, but the reason for the gain remains unclear. - The October 14 close was $1.12; coverage found no...
🟢 Spero Therapeutics is trading 5.8% up in pre-market
Spero Therapeutics is trading 5.83% up at $1.27 in pre-market, with no clear catalyst identified for the October 12 move. - Its latest listed release was an...
🟢 Spero Therapeutics rises 5.8% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🟢 Spero Therapeutics is trading 5% up in pre-market
Spero Therapeutics is trading 5.26% higher at $1.20 in pre-market on October 9, 2026; the reason for the move remains unclear. - The latest located company...
🟢 Spero Therapeutics is trading 7.6% up in pre-market — with no clear catalyst identified
Spero Therapeutics is trading at $1.28, up 7.56%, in pre-market, with no clear company-specific catalyst identified. - The latest company release, dated...
🟢 Spero Therapeutics is trading 7.8% up in pre-market with no clear company-specific catalyst
Spero Therapeutics is trading at $1.25, up 7.75% in pre-market, with no clear company-specific catalyst. - No new company-specific announcement surfaced for...
🔴 Spero Therapeutics is trading 5% down with no clear catalyst identified
Spero Therapeutics is trading 5.16% lower at $1.20 on October 2, 2026, with no clear company-specific catalyst identified in available search results. -...
🟢 Spero Therapeutics is trading 5% up; no clear catalyst identified
Spero Therapeutics is trading at $1.27, up 5.37%, with no specific reason for the move established for October 1, 2026. - No clear company-specific...
🟢 Spero Therapeutics is trading 5.6% up in pre-market as major indices rise
Spero Therapeutics is trading 5.6% higher at $1.32, possibly reflecting improved pre-market risk appetite, though confidence in that explanation is limited. -...
🔴 Spero Therapeutics is trading 5.2% down today amid apparent profit-taking after prior session's 19.30% gain
Spero Therapeutics is trading 5.2% lower at $1.29, with the decline appearing consistent with profit-taking after the prior session’s 19.30% gain. - It opened...
🟢 Spero Therapeutics is trading 12.72% up today with no new company-specific announcement identified
Spero Therapeutics is trading 12.72% up at $1.28, with no new company-specific announcement identified for September 22, 2026. - The latest notable filing was...
🟢 Spero Therapeutics is trading 6.19% up in pre-market amid broad pre-market strength
Spero Therapeutics is trading at $1.20 (+6.19%) in pre-market amid broad risk-on sentiment. - No fresh company-specific announcement was identified for...
Spero Therapeutics Establishes $100 Million At-The-Market Offering Program with Jefferies
Spero Therapeutics announced it has entered into an Open Market Sale Agreement with Jefferies LLC to establish a new at-the-market (ATM) offering program. This...
Alphabet Buys 1.5% Stake in Spero Therapeutics for $2 Million
Alphabet Inc. established a new position in Spero Therapeutics during the second quarter. The technology giant purchased 889,979 shares of the clinical-stage...
🟢 Spero Therapeutics is trading 6.72% up today after Q2 earnings and $105 million royalty financing
Spero Therapeutics is trading 6.72% up at $1.27 after its August 12, 2026 earnings release highlighted FDA-approved Utebzi and a $105 million non-dilutive...
🟢 Spero Therapeutics is trading 6.72% up in pre-market after Q2 earnings beat estimates
Spero Therapeutics is trading at $1.27 (+6.72%) in pre-market after Q2 2026 earnings beat estimates. - Q2 2026 adjusted loss was $0.16 per share, beating the...
Spero Therapeutics reported second quarter 2026 EPS of -$0.16 following FDA approval of Utebzi
Spero Therapeutics reported a net loss of $9.6 million on zero revenue for the second quarter of 2026 as the company transitions its focus toward its new...